Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin structure infections.
Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin structure infections. by Sader HS, Mallick R, Kuznik A, Fritsche TR and Jones RN published in Int. J. Antimicrob Agents 2007; 30 (6): 514-520
